Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Net Margin (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Net Margin over the past 3 years, most recently at 870.32% for Q4 2025.

  • Quarterly results put Net Margin at 870.32% for Q4 2025, down 1408.0% from a year ago — trailing twelve months through Dec 2025 was 946.22% (up 34203.0% YoY), and the annual figure for FY2025 was 946.22%, up 34203.0%.
  • Net Margin for Q4 2025 was 870.32% at Tonix Pharmaceuticals Holding, up from 972.95% in the prior quarter.
  • Over the last five years, Net Margin for TNXP hit a ceiling of 503.65% in Q3 2024 and a floor of 3567.75% in Q2 2024.
  • Median Net Margin over the past 3 years was 800.11% (2023), compared with a mean of 1064.1%.
  • Biggest five-year swings in Net Margin: plummeted -276764bps in 2024 and later skyrocketed 215274bps in 2025.
  • Tonix Pharmaceuticals Holding's Net Margin stood at 723.0% in 2023, then dropped by -18bps to 856.24% in 2024, then fell by -2bps to 870.32% in 2025.
  • The last three reported values for Net Margin were 870.32% (Q4 2025), 972.95% (Q3 2025), and 1415.02% (Q2 2025) per Business Quant data.